

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/654,543	09/02/2003	Charanpreet S. Bagga	OVIT-0252	3970	
23377 WOODCOCK	7590 10/16/2007 WASHBURN LLP		EXAMINER		
CIRA CENTRE, 12TH FLOOR			PHILOGENE, PEDRO		
2929 ARCH ST	TREET IIA, PA 19104-2891		ART UNIT	PAPER NUMBER	
	111, 111 1510 1 2051		3733		
	•		MAIL DATE	DELIVERY MODE	
			10/16/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

1	Application No.	Applicant(s)				
Office Action Comments	10/654,543	BAGGA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Pedro Philogene	3733				
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with t	he correspondence address				
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory perions are provided for reply will, by state the provided period for reply will, by state and patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply of will apply and will expire SIX (6) MONTHS ute, cause the application to become ABANE	TION.  be timely filed  from the mailing date of this communication.  ONED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 02	August 2007					
	nis action is non-final.					
and the second	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	•	•				
Disposition of Claims						
4)⊠ Claim(s) 1-9 and 56-59 is/are pending in the	application.					
4a) Of the above claim(s) is/are withdo	rawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-9 and 56-59</u> is/are rejected.	<u> </u>					
7) Claim(s) is/are objected to.	•					
8) Claim(s) are subject to restriction and	l/or election requirement.					
Application Papers						
9) The specification is objected to by the Exami	ner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ ad	ccepted or b) objected to by t	he Examiner.				
Applicant may not request that any objection to the	ne drawing(s) be held in abeyance.	See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the corre	ection is required if the drawing(s) i	s objected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the	Examiner. Note the attached O	fice Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C. § 11	9(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:		•				
1. Certified copies of the priority docume						
2. Certified copies of the priority docume						
<ol><li>Copies of the certified copies of the pr</li></ol>	•	eived in this National Stage				
application from the International Bure	`					
* See the attached detailed Office action for a li	st of the certified copies not rec	eived.				
Attachment(s)	<u>.</u>					
1) Notice of References Cited (PTO-892)		nary (PTO-413) ail Date				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)		nal Patent Application				
Paper No(s)/Mail Date <u>9/12/07</u> .	6) Other:					

#### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/2/07 has been entered.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-9,56-59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Reiley et al. (7,081,122) in view of Moaddeb (6,671,561).

With respect to the above claims, Reiley et al disclose kit for delivery of a composition into an intraosseous space comprising at least one cannula (50) at least one stylet (23) insertable into a cannula and being movable therein, at least one catheter (130) that is insertable into the cannula; and a system (136,140,142) for delivery of aliquots of the composition into the intraosseous space via the catheter; asset forth in column 4, lines 14-25, column 7, lines 39-59, column 8, lines 35-67, column 9, lines 1-67, column 10, lines 1-14.

Application/Control Number: 10/654,543

Art Unit: 3733

It is noted that Reiley et al did not teach of a catheter having a substantially rigid high-porosity tip; as claimed by applicant. However, in a similar art, Maddeb, column 3, lines 20-67, column 4, lines 1-67 evidences the use of a catheter having a substantially high-porosity tip to prevent damage to the interior walls of the heart or blood vessels.

Therefore, given the teaching of Motoda, it would have been obvious to one having ordinary skill in the art at the time the invention to modify the tip of the catheter of Reiley et al, as taught by Motoda to prevent damage to the interior walls of the heart or blood vessels.

## Response to Amendment

Applicant's arguments, see Remarks, filed 8/2/07, with respect to the rejection(s) of claim(s) 1-9, 56-59 under 103 have been fully considered and are persuasive.

Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Moaddeb.

#### Conclusion

A shortened statutory period for reply to this action is set to expire THREE MONTHS from the mailing date of this action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pedro Philogene whose telephone number is (571) 272-4716. The examiner can normally be reached on Monday to Friday 6:30 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eduardo Robert can be reached on (571) 272 - 4719. The fax phone

Application/Control Number: 10/654,543

Art Unit: 3733

number for the organization where this application or proceeding is assigned is 571-273-8300.

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Pedro Philogene October 8, 2007